Sorrento Provides Manufacturing Support for COVID-19 Treatment; What’s Next?

The battle against COVID-19 is well underway, and now’s the time to send in the big guns. Sorrento Therapeutics (SRNE) is on it, offering both active and passive immunization strategies. As a result, it has received positive investor attention, as demonstrated by its 35% one-month gain.As part of these efforts, the healthcare name, which develops therapies to reduce the malignancy of life-threatening tumors, improves the safety of current treatments and brings solutions to make living with cancer more tolerable, partnered with Celularity. Celularity is a privately-held cell therapeutics company that specializes in transformative allogeneic cellular therapies developed from the postpartum …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.